Christophe Le Tourneau

39PUBLICATIONS
187CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursPredictive and prognostic markersNeurosciences not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Nov 12, 2025
An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.

Isabella Hofer, Yann Kieffer, Arianna Mencattini

|Sep 12, 2025
Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023.

Matthias Monnereau, Jean-Pierre Delord, Stefan Michiels

|Sep 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

Abderaouf Hamza, Pierre Gestraud, Maryam Karimi

|Jun 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Edith Borcoman, Bastien Cabarrou, Miguel Francisco

|Jun 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.

Ravindra Uppaluri, Robert I Haddad, Yungan Tao

Pageof 7

Frequent Collaborators

8 joint publications

Maud Kamal

7 joint publications

Nicolas Servant

6 joint publications

Fabrice Andre

4 joint publications

Marta Jimenez